AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial
The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney
AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabe
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
